# The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

> **NCT00438789** · — · APPROVED_FOR_MARKETING · sponsor: **Alexion Pharmaceuticals, Inc.**

## Conditions studied

- Hemoglobinuria, Paroxysmal

## Interventions

- **DRUG:** eculizumab

## Key facts

- **NCT ID:** NCT00438789
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00438789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00438789, "The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT00438789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*